Evolving management of colorectal cancer

World Journal of Gastroenterology

Volumn 14, Issue 25, 2008, Pages 3956-3967

  van der Voort van Zijp, Jochem ^a   Hoekstra, Harald J ^b   Basson, Marc D ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Adhesion; Cancer; Colorectal; Signaling; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; FLUOROURACIL; FOCAL ADHESION ASSOCIATED PROTEIN; FOCAL ADHESION KINASE; FOLINIC ACID; INTEGRIN; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CELL ADHESION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; EXTRACELLULAR MATRIX; HUMAN; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; PERITONEUM METASTASIS; PREVALENCE; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; UNSPECIFIED SIDE EFFECT; WOUND; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COLON RESECTION; COLORECTAL TUMOR; INCIDENCE; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLORECTAL NEOPLASMS; HUMANS; INCIDENCE; NEOPLASM METASTASIS; NEOPLASM STAGING; PREVALENCE; RADIOTHERAPY, ADJUVANT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 53449084494     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3956     Document Type: Review

References (150)

1. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-1371
2. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168
3. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560
4. Lieberman DA, Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, Schnell TG, Chejfec G, Campbell DR, Kidao J, Bond JH, Nelson DB, Triadafilopoulos G, Ramirez FC, Collins JF, Johnston TK, McQuaid KR, Garewal H, Sampliner RE, Esquivel R, Robertson D. Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007; 133: 1077-1085
5. National Cancer Institute. A snapshot of Colorectal Cancer 2005, 2007
6. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53: 371-376
7. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, J. Cancer Incidence in five continents, Vol. 6 Lyon, France: International agency for research on Cancer, 1992; 120: 301-353
8. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997; 40: 483-493
9. Fahy B, Bold RJ. Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 1998; 7: 115-123
10. Vereniging van Integrale Kankercentra. Aantal nieuwe patienten, leeftijdsverdeling, percentage kankerpatienten en risico, 2007
11. Koningin Wilhelmina Fonds. Cijfers over dikke darmkanker, 2006
12. Damjanov N, Meropol NJ. Oral therapy for colorectal cancer: how to choose. Oncology (Williston Park) 2000; 14: 799-807; discussion 807-808, 813-814,
13. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425
14. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552
15. Turnbull RB Jr, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 1967; 166: 420-427
16. Hida J, Yasutomi M, Maruyama T, Fujimoto K, Uchida T, Okuno K. The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer 1997; 80: 188-192
17. Bruch HP, Schwandner O, Keller R. [Limitations of laparoscopic visceral surgery in oncology] Chirurg 2003; 74: 290-300
18. Bruch HP, Schwandner O, Schiedeck TH, Roblick UJ. Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer. Langenbecks Arch Surg 1999; 384: 167-175
19. Schwandner O, Schiedeck TH, Killaitis C, Bruch HP. A case-control-study comparing laparoscopic versus open surgery for rectosigmoidal and rectal cancer. Int J Colorectal Dis 1999; 14: 158-163
20. Wiggers T, Jeekel J, Arends JW, Brinkhorst AP, Kluck HM, Luyk CI, Munting JD, Povel JA, Rutten AP, Volovics A. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 1988; 75: 409-415
21. Fujita S, Kudo N, Akasu T, Moriya Y. Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their prognosis. Int J Colorectal Dis 2001; 16: 141-146
22. Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-775; discussion 775-776
23. Hayashi N, Egami H, Kai M, Kurusu Y, Takano S, Ogawa M. No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. Surgery 1999; 125: 369-374
24. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982; 69: 613-616
25. Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg 2004; 240: 260-268
26. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335-346
27. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460
28. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-96
29. Arenas RB, Fichera A, Mhoon D, Michelassi F. Total mesenteric excision in the surgical treatment of rectal cancer: a prospective study. Arch Surg 1998; 133: 608-611; discussion 611-612
30. Tocchi A, Mazzoni G, Lepre L, Liotta G, Costa G, Agostini N, Miccini M, Scucchi L, Frati G, Tagliacozzo S. Total mesorectal excision and low rectal anastomosis for the treatment of rectal cancer and prevention of pelvic recurrences. Arch Surg 2001; 136: 216-220
31. Moore HG, Riedel E, Minsky BD, Saltz L, Paty P, Wong D, Cohen AM, Guillem JG. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol 2003; 10: 80-85
32. Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002; 89: 1142-1149
33. Group. TCOoSTS. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059
34. Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002; 359: 2224-2229
35. Jacobs M, Verdeja JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy). Surg Laparosc Endosc 1991; 1: 144-150
36. Braga M, Vignali A, Gianotti L, Zuliani W, Radaelli G, Gruarin P, Dellabona P, Di Carlo V. Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg 2002; 236: 759-766; disscussion 767
37. Chapman AE, Levitt MD, Hewett P, Woods R, Sheiner H, Maddern GJ. Laparoscopic-assisted resection of colorectal malignancies: a systematic review. Ann Surg 2001; 234: 590-606
38. Mathew G, Watson DI, Rofe AM, Ellis T, Jamieson GG. Adverse impact of pneumoperitoneum on intraperitoneal implantation and growth of tumour cell suspension in an experimental model. Aust N Z J Surg 1997; 67: 289-292
39. Wysocki A. [Does the laparoscopic technique influence the intraperitoneal tumor dissemination?] Przegl Lek 2000; 57: 195-197
40. Jingli C, Rong C, Rubai X. Influence of colorectal laparoscopic surgery on dissemination and seeding of tumor cells. Surg Endosc 2006; 20: 1759-1761
41. Buchmann P, Christen D, Moll C, Flury R, Sartoretti C. [Tumor cells in peritoneal irrigation fluid in conventional and laparoscopic surgery for colorectal carcinoma] Swiss Surg 1996; Suppl 4: 45-49
42. Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure of malignancy. Br J Surg 1995; 82: 295-298
43. Neuhaus SJ, Texler M, Hewett PJ, Watson DI. Port-site metastases following laparoscopic surgery. Br J Surg 1998; 85: 735-741
44. Prasad A, Avery C, Foley RJ. Abdominal wall metastases following laparoscopy. Br J Surg 1994; 81: 1697
45. Berends FJ, Kazemier G, Bonjer HJ, Lange JF. Subcutaneous metastases after laparoscopic colectomy. Lancet 1994; 344: 58
46. Leung KL, Kwok SP, Lam SC, Lee JF, Yiu RY, Ng SS, Lai PB, Lau WY. Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 2004; 363: 1187-1192
47. Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, Beutler T, Wiese D, Bassily N, Yee C. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 2006; 191: 305-310
48. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-1887
49. Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124: 1016-1025
50. Herrera-Ornelas L, Justiniano J, Castillo N, Petrelli NJ, Stulc JP, Mittelman A. Metastases in small lymph nodes from colon cancer. Arch Surg 1987; 122: 1253-1256
51. Rodriguez-Bigas MA, Maamoun S, Weber TK, Penetrante RB, Blumenson LE, Petrelli NJ. Clinical significance of colorectal cancer: metastases in lymph nodes < 5 mm in size. Ann Surg Oncol 1996; 3: 124-130
52. Stojadinovic A, Nissan A, Protic M, Adair CF, Prus D, Usaj S, Howard RS, Radovanovic D, Breberina M, Shriver CD, Grinbaum R, Nelson JM, Brown TA, Freund HR, Potter JF, Peretz T, Peoples GE. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. Ann Surg 2007; 245: 846-857
53. Bilchik AJ, Nora D, Tollenaar RA, van de Velde CJ, Wood T, Turner R, Morton DL, Hoon DS. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer 2002; 38: 977-985
54. Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha S, Krasne D, Morton DL. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol 2003; 21: 668-672
55. Wong JH, Johnson DS, Namiki T, Tauchi-Nishi P. Validation of ex vivo lymphatic mapping in hematoxylin-eosin nodenegative carcinoma of the colon and rectum. Ann Surg Oncol 2004; 11: 772-777
56. Saha S, Dan AG, Beutler T, Wiese D, Schochet E, Badin J, Branigan T, Ng P, Bassily N, David D. Sentinel lymph node mapping technique in colon cancer. Semin Oncol 2004; 31: 374-381
57. Bilchik AJ, DiNome M, Saha S, Turner RR, Wiese D, McCarter M, Hoon DS, Morton DL. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg 2006; 141: 527-533; discussion 533-534
58. Fricker J. Sentinel-node mapping for staging of colorectal cancer. Lancet Oncol 2006; 7: 291
59. Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-710; discussion 710-711
60. Beckurts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081-1084
61. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231: 743-751
62. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766
63. Van Ooijen B, Wiggers T, Meijer S, van der Heijde MN, Slooff MJ, van de Velde CJ, Obertop H, Gouma DJ, Bruggink ED, Lange JF. Hepatic resections for colorectal metastases in The Netherlands. A multiinstitutional 10-year study. Cancer 1992; 70: 28-34
64. Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131: 322-329
65. Lind DS, Parker GA, Horsley JS 3rd, Kornstein MJ, Neifeld JP, Bear HD, Lawrence W Jr. Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis. Ann Surg 1992; 215: 677-683; discussion 683-684
66. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135
67. Minagawa M, Yamamoto J, Miwa S, Sakamoto Y, Kokudo N, Kosuge T, Miyagawa S, Makuuchi M. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg 2006; 141: 1006-1012; discussion 1013
68. Cady B, Stone MD, McDermott WV Jr, Jenkins RL, Bothe A Jr, Lavin PT, Lovett EJ, Steele GD Jr. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 1992; 127: 561-568; discussion 568-569
69. Curley SA. Radiofrequency ablation of malignant liver tumors. Oncologist 2001; 6: 14-23
70. Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001; 6: 24-33
71. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825; discussion 825-827
72. Elias D, Goharin A, El Otmany A, Taieb J, Duvillard P, Lasser P, de Baere T. Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatectomy. Eur J Surg Oncol 2000; 26: 763-769
73. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10: 1059-1069
74. De Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000; 175: 1619-1625
75. Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91: 1066-1071
76. Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003; 126: 732-739
77. Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, Yokouchi H. Surgery for pulmonary metastases from colorectal cancer: the importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Jpn J Thorac Cardiovasc Surg 2003; 51: 289-296
78. Ishikawa K, Hashiguchi Y, Mochizuki H, Ozeki Y, Ueno H. Extranodal cancer deposit at the primary tumor site and the number of pulmonary lesions are useful prognostic factors after surgery for colorectal lung metastases. Dis Colon Rectum 2003; 46: 629-636
79. Ike H, Shimada H, Ohki S, Togo S, Yamaguchi S, Ichikawa Y. Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45: 468-473; discussion 473-475
80. Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007-1013
81. Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, Filosso PL, Maggi G. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002; 21: 906-912
82. Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119: 1069-1072
83. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, Baldeyrou P, Levasseur P. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214-218; discussion 218-219
84. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-785; discussion 785-786
85. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, Lasser P, Gayet B, Ruffie P, Grunenwald D. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996; 14: 2047-2053
86. Inoue M, Kotake Y, Nakagawa K, Fujiwara K, Fukuhara K, Yasumitsu T. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000; 70: 380-383
87. Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suemasu K. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64: 1418-1421
88. Van Halteren HK, Van Geel AN, Hart AA, Zoetmulder FA. Pulmonary resection for metastases of colorectal origin. Chest 1995; 107: 1526-1531
89. Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, Naruke T. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112: 867-874
90. Yano T, Hara N, Ichinose Y, Yokoyama H, Miura T, Ohta M. Results of pulmonary resection of metastatic colorectal cancer and its application. J Thorac Cardiovasc Surg 1993; 106: 875-879
91. Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82: 254-260
92. Party. MRCRCW. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party. Lancet 1996; 348: 1605-1610
93. Trial. SRC. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980-987
94. Marijnen CA, Nagtegaal ID, Klein Kranenbarg E, Hermans J, van de Velde CJ, Leer JW, van Krieken JH. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984
95. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, Kryj M, Oledzki J, Szmeja J, Sluszniak J, Serkies K, Kladny J, Pamucka M, Kukolowicz P. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24
96. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123
97. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740
98. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-56
99. Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer 2007; 97: 1333-1337
100. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408
101. Hospers GA, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, Marijnen CA, Jansen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007; 14: 2773-2779
102. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006; 17: 361-371
103. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104
104. Moosmann N, Laessig D, Michaely HJ, Schulz C, Heinemann V. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie 2007; 30: 509-512
105. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
106. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM. Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106
107. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14: 759-765
108. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115-1122
109. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43 Suppl: S15-S25
110. Nduka CC, Darzi A. Port-site metastasis in patients undergoing laparoscopy for gastrointestinal malignancy. Br J Surg 1997; 84: 583
111. McCarthy RA, Hay ED. Collagen I, laminin, and tenascin: ultrastructure and correlation with avian neural crest formation. Int J Dev Biol 1991; 35: 437-452
112. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25
113. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991; 65: 359-362
114. Eckmann L, Huang GT, Smith JR, Morzycka-Wroblewska E, Kagnoff MF. Increased transcription and coordinate stabilization of mRNAs for secreted immunoglobulin alpha heavy chain and kappa light chain following stimulation of immunoglobulin A expressing B cells. J Biol Chem 1994; 269: 33102-33108
115. Yazawa K, Tsuno NH, Kitayama J, Kawai K, Okaji Y, Asakage M, Sunami E, Kaisaki S, Hori N, Watanabe T, Takahashi K, Nagawa H. Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci 2005; 96: 93-99
116. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003; 90: 1055-1067
117. Lee SW, Gleason NR, Bessler M, Whelan RL. Peritoneal irrigation with povidone-iodine solution after laparoscopic-assisted splenectomy significantly decreases port-tumor recurrence in a murine model. Dis Colon Rectum 1999; 42: 319-326
118. Watson DI, Ellis T, Leeder PC, Neuhaus SJ, Dodd T, Jamieson GG. Excision of laparoscopic port sites increases the likelihood of wound metastases in an experimental model. Surg Endosc 2003; 17: 83-85
119. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-4068
120. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-1347
121. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 62: 2029-2033
122. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002; 531: 278-284
123. Grzesiak JJ, Pierschbacher MD. Shifts in the concentrations of magnesium and calcium in early porcine and rat wound fluids activate the cell migratory response. J Clin Invest 1995; 95: 227-233
124. Ebert EC. Mechanisms of colon cancer binding to substratum and cells. Dig Dis Sci 1996; 41: 1551-1556
125. Thamilselvan V, Fomby M, Walsh M, Basson MD. Divalent cations modulate human colon cancer cell adhesion. J Surg Res 2003; 110: 255-265
126. Van der Voort van Zyp J, Conway WC, Thamilselvan V, Polin L, Basson MD. Divalent cations influence colon cancer cell adhesion in a murine transplantable tumor model. Am J Surg 2005; 190: 701-707
127. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458
128. Dregelid E, Svendsen E. Endothelial cell injury in human saphenous veins after manipulation and tweezer grasping. J Cardiovasc Surg (Torino) 1988; 29: 464-469
129. Fraunfelder FT, Boozman FW, Wilson RS, Thomas AH. Notouch technique for intraocular malignant melanomas. Arch Ophthalmol 1977; 95: 1616-1620
130. Basson MD, Yu CF, Herden-Kirchoff O, Ellermeier M, Sanders MA, Merrell RC, Sumpio BE. Effects of increased ambient pressure on colon cancer cell adhesion. J Cell Biochem 2000; 78: 47-61
131. Thamilselvan V, Patel A, van der Voort van Zyp J, Basson MD. Colon cancer cell adhesion in response to Src kinase activation and actin-cytoskeleton by non-laminar shear stress. J Cell Biochem 2004; 92: 361-371
132. Van der Voort van Zyp J, Thamilselvan V, Walsh M, Polin L, Basson MD. Extracellular pressure stimulates colon cancer cell adhesion in vitro and to surgical wounds by Src (sarcoma protein) activation. Am J Surg 2004; 188: 467-473
133. Shiratsuchi H, Ellner JJ, Basson MD. Extracellular-regulated kinase activation regulates replication of Mycobacterium avium intracellularly in primary human monocytes. Cell Tissue Res 2008; 332: 237-244
134. Longhurst CM, Jennings LK. Integrin-mediated signal transduction. Cell Mol Life Sci 1998; 54: 514-526
135. Kim M, Javed NH, Yu JG, Christofi F, Cooke HJ. Mechanical stimulation activates Galphaq signaling pathways and 5-hydroxytryptamine release from human carcinoid BON cells. J Clin Invest 2001; 108: 1051-1059
136. Thamilselvan V, Basson MD. Pressure activates colon cancer cell adhesion by inside-out focal adhesion complex and actin cytoskeletal signaling. Gastroenterology 2004; 126: 8-18
137. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002; 4: 191-194
138. Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 2001; 22: 1035-1042
139. Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005; 280: 20968-20977
140. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102
141. Phillips WA, St Clair F, Munday AD, Thomas RJ, Mitchell CA. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998; 83: 41-47
142. Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 2007; 21: 1730-1741
143. Wang S, Basson MD. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. Exp Cell Res 2008; 314: 286-296
144. Thamilselvan V, Basson MD. The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell adhesion. Carcinogenesis 2005; 26: 1687-1697
145. Van Zyp JV, Conway WC, Craig DH, van Zyp NV, Thamilselvan V, Basson MD. Extracellular pressure stimulates tumor cell adhesion in vitro by paxillin activation. Cancer Biol Ther 2006; 5: 1169-1178
146. Conway WC, Van der Voort van Zyp J, Thamilselvan V, Walsh MF, Crowe DL, Basson MD. Paxillin modulates squamous cancer cell adhesion and is important in pressure-augmented adhesion. J Cell Biochem 2006; 98: 1507-1516
147. Craig DH, Haimovich B, Basson MD. Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction. Am J Physiol Cell Physiol 2007; 293: C1862-C1874
148. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku T, Takagi R. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003; 106: 683-689
149. Azuma K, Tanaka M, Uekita T, Inoue S, Yokota J, Ouchi Y, Sakai R. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-4764
150. Prados J, Melguizo C, Fernandez JE, Aranega AE, Alvarez L, Aranega A. Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide. Cell Mol Biol (Noisy-le-grand) 1993; 39: 525-536